Effect of raloxifene (a Selective Estrogen Receptor Modulator (SERM)) as coadjuvant to antidepressant treatment: A case report

Authors

  • Judith Usall Sant Joan de Déu-SSM Fundació Sant Joan de Déu; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM)
  • Marta Coromina Sant Joan de Déu-SSM Fundació Sant Joan de Déu; Grup de Treball i Recerca en Dona i Salut Mental
  • Susana Araya Sant Joan de Déu-SSM Fundació Sant Joan de Déu
  • Susana Ochoa Sant Joan de Déu-SSM Fundació Sant Joan de Déu; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM) ; Grup de Treball i Recerca en Dona i Salut Mental

Keywords:

Raloxifene, Treatment, Depressive disorder, Estrogens

Abstract

We report a case of a woman with a depressive disorder with partial response to antidepressant treatment. Raloxifene, a Selective Estrogen Receptor Modulator (SERM) was added to the treatment, the patient achieving complete remission of her depressive symptoms. The interest of our case lies in the fact that it exemplifies the relationship between depressive disorders and hormonal changes during menopause. Furthermore, raloxifene may become a novel therapeutic option in some postmenopausal women who do not respond or only partially respond to SSRIs, especially in those with a history of depressive disorders related to menopause.

Downloads

Published

2011-09-01

How to Cite

Usall, Judith, et al. “Effect of Raloxifene (a Selective Estrogen Receptor Modulator (SERM)) As Coadjuvant to Antidepressant Treatment: A Case Report”. Actas Españolas De Psiquiatría, vol. 39, no. 5, Sept. 2011, pp. 334-5, https://actaspsiquiatria.es/index.php/actas/article/view/791.

Issue

Vol. 39 No. 5 (2011)

Section

Clinical Note